Targeting of AKT-Signaling Pathway Potentiates the Anti-cancer Efficacy of Doxorubicin in A673 Ewing Sarcoma Cell Line

2021 ◽  
Author(s):  
A. Galembikova ◽  
S. Boichuk
Keyword(s):  
Cell Line ◽  
Signaling Pathway ◽  
Ewing Sarcoma ◽  
Akt Signaling ◽  
Akt Signaling Pathway ◽  
Sarcoma Cell ◽  
Sarcoma Cell Line ◽  
Anti Cancer

Biological role of AKT, and regulation of AKT signaling pathway by thymoquinone: perspectives in cancer therapeutics

2020 ◽  
Vol 20 ◽  
Author(s):  
Md. Junaid ◽  
Yeasmin Akter ◽  
Syeda Samira Afrose ◽  
Mousumi Tania ◽  
Md. Asaduzzaman Khan
Keyword(s):  
Clinical Trials ◽  
Signaling Pathways ◽  
Signaling Pathway ◽  
Inhibitory Effect ◽  
Akt Signaling ◽  
Review Article ◽  
Therapeutic Drug ◽  
Akt Signaling Pathway ◽  
Anti Cancer

Background: AKT/PKB is an important enzyme with numerous biological functions, and its overexpression is related to the carcinogenesis. AKT stimulates different signaling pathways that are downstream of activated tyrosine kinases and phosphatidylinositol 3-kinase, hence functions as an important target for anti-cancer drugs. Objective: In this review article, we have interpreted the role of AKT signaling pathways in cancer and natural inhibitory effect of Thymoquinone (TQ) in AKT and its possible mechanism. Method: We have collected the updated information and data on AKT, their role in cancer and inhibitory effect of TQ in AKT signaling pathway from google scholar, PubMed, Web of Science, Elsevier, Scopus and many more. Results: There are many drugs already developed, which can target AKT, but very few among them have passed clinical trials. TQ is a natural compound, mainly found in black cumin, which has been found to have potential anti-cancer activities. TQ targets numerous signaling pathways, including AKT, in different cancers. In fact, many studies revealed that AKT is one of the major targets of TQ. The preclinical success of TQ suggests its clinical studies on cancer. Conclusion: This review article summarizes the role of AKT in carcinogenesis, its potent inhibitors in clinical trials, and how TQ acts as an inhibitor of AKT and TQ’s future as a cancer therapeutic drug.

Osteosarcomatous features in a transplanted Ewing sarcoma cell line (6647): Histological and molecular biology analysis

1992 ◽  
Vol 63 (2) ◽  
pp. 165
Author(s):  
A. Pagani ◽  
B. Sanfilippo ◽  
G. Ponzio ◽  
G. Restagno ◽  
A.O. Carbonara ◽  
...  
Keyword(s):  
Molecular Biology ◽  
Cell Line ◽  
Ewing Sarcoma ◽  
Sarcoma Cell ◽  
Sarcoma Cell Line

scholarly journals Epigenetic reprogramming and re-differentiation of a Ewing sarcoma cell line

2015 ◽  
Vol 3 ◽  
Author(s):  
Joseph B. Moore ◽  
David M. Loeb ◽  
Kyung U. Hong ◽  
Poul H. Sorensen ◽  
Timothy J. Triche ◽  
...  
Keyword(s):  
Cell Line ◽  
Ewing Sarcoma ◽  
Epigenetic Reprogramming ◽  
Sarcoma Cell ◽  
Sarcoma Cell Line

scholarly journals Anti-tumor activity of Shikonin against afatinib resistant non-small cell lung cancer via negative regulation of PI3K/Akt signaling pathway

2018 ◽  
Vol 38 (6) ◽  
Author(s):  
Baiying Li ◽  
Zuguo Yuan ◽  
Jin Jiang ◽  
Yuanquan Rao
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Signaling Pathway ◽  
Cell Lung Cancer ◽  
Akt Signaling ◽  
Small Cell ◽  
Nsclc Cell Line ◽  
Akt Signaling Pathway ◽  
Small Cell Lung ◽  
Anti Cancer

Acquired resistance of afatinib is a significant challenge for non-small cell lung cancer (NSCLC) therapy and the mechanisms remain unclear. Aberrant activation of epidermal growth factor receptor (EGFR)-dependent downstream pathways, especially phosphatidylinositol-3-kinases/protein kinase B (PI3K/Akt) signaling pathway has been reported to be involved in the occurrence of afatinib resistance. Developing effective anti-cancer agents to overcome afatinib resistance by targetting PI3K/Akt signaling pathway will be a potential strategy for NSCLC treatment. Shikonin is a naphthoquinone compound isolated from the roots of Lithospermum erythrorhizon. In the present study, the anti-cancer activity of Shikonin was evaluated on afatinib-resistant NSCLC in vitro and in vivo. The data showed that Shikonin inhibited the proliferation and induced apoptosis of afatinib-resistant NSCLC cell line by activating apoptosis signaling pathway and negatively regulating PI3K/Akt signaling pathway. These results revealed that Shikonin was a potential apoptosis inducer in afatinib-resistant NSCLC and a promising candidate for treating patients clinically.

Sign in / Sign up

Export Citation Format

Share Document